Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection
Objective: Given the urgent need for strategies to minimize the damage caused by this pandemic, this study performed a randomized, double-blind phase 2 study to assess the safety of the effectiveness of chloroquine (CQ), hydroxychloroquine (HCQ) or ivermectin in severe forms of COVID-19, in addition to identifying predictors of mortality in this group of patients.Methods: Phase 2, double-blind, randomized study to assess the safety and efficacy of enteral CQ, HCQ or ivermectin in patients hospitalized for SARS-CoV-2 infection, admitted to a Reference Hospital in Roraima (Brazil) in may 2020. Patients were randomized in a 1:1:1 ratio. The endpoints were need of supplemental O2, invasive ventilation, admission in ICU and death. The study was approved by an independent IRB.Results: 168 patients were randomized. The mean age was 53.4 years (±15.6), most participants were male (n = 95; 58.2%). Therapy with corticosteroid, anticoagulant or antibiotics was a decision of the attending physicians, and there was no difference between the groups. The mortality was similar in three groups (22.2%; 21.3% and 23.0%) suggesting ineffectiveness of the drugs. No difference in the incidence of serious adverse events were observed. To be older than 60 years of age, obesity, diabetes, extensive pulmonary involvement and low SaO2 at hospital admission due to independent risk factors for mortality.Conclusion: Although CQ, HCQ or ivermectin revealed a favorable safety profile, the tested drugs do not reduce the need for supplemental oxygen, ICU admission, invasive ventilation or death, in patients hospitalized with a severe form of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
|---|---|
| Enthalten in: |
Pathogens and global health - 115(2021), 4 vom: 18. Juni, Seite 235-242 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Galan, Luis Enrique Bermejo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 11.06.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/20477724.2021.1890887 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322398665 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322398665 | ||
| 003 | DE-627 | ||
| 005 | 20231225181946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/20477724.2021.1890887 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322398665 | ||
| 035 | |a (NLM)33682640 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galan, Luis Enrique Bermejo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.06.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: Given the urgent need for strategies to minimize the damage caused by this pandemic, this study performed a randomized, double-blind phase 2 study to assess the safety of the effectiveness of chloroquine (CQ), hydroxychloroquine (HCQ) or ivermectin in severe forms of COVID-19, in addition to identifying predictors of mortality in this group of patients.Methods: Phase 2, double-blind, randomized study to assess the safety and efficacy of enteral CQ, HCQ or ivermectin in patients hospitalized for SARS-CoV-2 infection, admitted to a Reference Hospital in Roraima (Brazil) in may 2020. Patients were randomized in a 1:1:1 ratio. The endpoints were need of supplemental O2, invasive ventilation, admission in ICU and death. The study was approved by an independent IRB.Results: 168 patients were randomized. The mean age was 53.4 years (±15.6), most participants were male (n = 95; 58.2%). Therapy with corticosteroid, anticoagulant or antibiotics was a decision of the attending physicians, and there was no difference between the groups. The mortality was similar in three groups (22.2%; 21.3% and 23.0%) suggesting ineffectiveness of the drugs. No difference in the incidence of serious adverse events were observed. To be older than 60 years of age, obesity, diabetes, extensive pulmonary involvement and low SaO2 at hospital admission due to independent risk factors for mortality.Conclusion: Although CQ, HCQ or ivermectin revealed a favorable safety profile, the tested drugs do not reduce the need for supplemental oxygen, ICU admission, invasive ventilation or death, in patients hospitalized with a severe form of COVID-19 | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a chloroquine | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a ivermectin | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Antiparasitic Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Ivermectin |2 NLM | |
| 650 | 7 | |a 70288-86-7 |2 NLM | |
| 650 | 7 | |a Chloroquine |2 NLM | |
| 650 | 7 | |a 886U3H6UFF |2 NLM | |
| 700 | 1 | |a Santos, Nayara Melo Dos |e verfasserin |4 aut | |
| 700 | 1 | |a Asato, Mauro Shosuka |e verfasserin |4 aut | |
| 700 | 1 | |a Araújo, Jucineide Vieira |e verfasserin |4 aut | |
| 700 | 1 | |a de Lima Moreira, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Araújo, Aléxia Mahara Marques |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, Artur Diogenes Pinheiro |e verfasserin |4 aut | |
| 700 | 1 | |a Portella, Diego Guilherme Santos |e verfasserin |4 aut | |
| 700 | 1 | |a Marques, Frank Silas Saldanha |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Gabriel Melo Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a de Sousa Resende, Joana |e verfasserin |4 aut | |
| 700 | 1 | |a Tizolim, Marycassiely Rodrigues |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Poliana Lucenados |e verfasserin |4 aut | |
| 700 | 1 | |a Buttenbender, Steffi Ferreira |e verfasserin |4 aut | |
| 700 | 1 | |a de Andrade, Stephanye Batista |e verfasserin |4 aut | |
| 700 | 1 | |a Carbonell, Roberto Carlos Cruz |e verfasserin |4 aut | |
| 700 | 1 | |a Da Rocha, Juliana Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza, Ruy Guilherme Silveira |e verfasserin |4 aut | |
| 700 | 1 | |a da Fonseca, Allex Jardim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathogens and global health |d 2012 |g 115(2021), 4 vom: 18. Juni, Seite 235-242 |w (DE-627)NLM217875459 |x 2047-7732 |7 nnns |
| 773 | 1 | 8 | |g volume:115 |g year:2021 |g number:4 |g day:18 |g month:06 |g pages:235-242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/20477724.2021.1890887 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 115 |j 2021 |e 4 |b 18 |c 06 |h 235-242 | ||